SCHEMBL4825624

SCHEMBL4825624

O=C(O)c1ccc2cc3n(c2c1)C=CCc1nccnc1-3

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
POLB P06746 1/20 0.33
FGFR1 P11362 1/20 0.33
P4HA1 P13674 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PLAU P00749 1/20 0.32
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.32
ENPP2 Q13822 1/20 0.32
RPS6KA3 P51812 2/20 0.32
RPS6KA2 Q15349 1/20 0.32
ACLY P53396 1/20 0.31
KDM4C Q9H3R0 2/20 0.31
KDM6B O15054 1/20 0.31
TET3 O43151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826983 0.86 SLC40A1 (0.36) POLBFGFR1SMN1; SMN2MEN1KMT2A
SCHEMBL4831483 0.83 SMN1; SMN2 (0.36) POLBFGFR1SMN1; SMN2MEN1KMT2A
SCHEMBL4828066 0.79 GAA (0.34) POLBFGFR1SMN1; SMN2MEN1KMT2A
SCHEMBL4830100 0.79 KDM4E (0.37) FGFR1KDM4EALDH1A1HSD17B10HPGD
SCHEMBL4830030 0.76 SLC22A12 (0.35) RPS6KA3RPS6KA2
SCHEMBL3244153 0.75 SRD5A2 (0.43) POLBFGFR1MEN1KMT2AKDM4E
SCHEMBL4829827 0.73 RPS6KA3 (0.41) FGFR1RPS6KA3RPS6KA2SLC40A1
SCHEMBL4826413 0.72 MAPK8 (0.34) FGFR1P4HA1PLAUKDM4EALDH1A1
SCHEMBL4823474 0.68 POLB (0.36) POLBFGFR1P4HA1SMN1; SMN2MEN1
SCHEMBL3075059 0.68 TBXA2R (0.36) POLBKMT2AKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348425-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-25 US disclosed
WO-2007092000-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-16 WO disclosed
EP-1776368-A1 INHIBITORS OF HCV REPLICATION Bristol-Myers Squibb Company (US) 2007-04-25 EP disclosed
US-7153848-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-26 US disclosed
US-20060166964-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 US disclosed
US-20060046983-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-03-02 US disclosed
WO-2006020082-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166964-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 CA12 4757/4885CA9 4545/4885POLB 89/4885
US-20060046983-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 CA12 4757/4885CA9 4545/4885POLB 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.